Glucagon-like peptide-1 receptor agonists and sarcopenia-related markers in diabetes: A systematic review and meta-analysis.
<p><b>AIMS</b></p><p>GLP-1 receptor agonists (GLP-1RAs) are first-line therapies for type 2 diabetes (T2DM) due to their additional weight-lowering and cardiovascular benefits. However, their impact on muscle mass is debated, posing a concern for sarcopenia in older adults with T2DM. This systematic...
